Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)

NCT05027867 is registered in ClinicalTrials.gov with Kartos Therapeutics, Inc. as lead sponsor.

NCT NCT05027867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05027867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Lead sponsor
Kartos Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 6, 2021
Completion date
August 26, 2022
Enrollment
3 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer extensive stage, small cell lung cancer recurrent, small cell lung carcinoma, small-cell lung cancer